Document is current
Any future updates will be listed below
-
Authors
Koeber, Ute
Matjusaitis, Mantas https://orcid.org/0000-0002-3740-2260
Alfazema, Neza
Furlong, Katharine https://orcid.org/0009-0001-3268-0763
Wang, Zeyu
White, Rachel
Hamdan, Alhafidz https://orcid.org/0000-0002-0794-5504
Dewari, Pooran
Morisse, Gregoire
Navarette, Mariela
Willis, Rosie
Wang, Jin
Clark, Michelle P. https://orcid.org/0000-0002-3723-3655
Jacinto de Sousa, Carla
Hong, Hei Ip
Sheraz, Shahida
Southgate, Ben
Cholewa-Waclaw, Justyna https://orcid.org/0000-0001-8625-8528
Gogolok, Sabine
Morrison, Gillian M.
Cancino, Felipe Galvez
Robertson, Faye https://orcid.org/0000-0002-7335-8308
Williams, Anna https://orcid.org/0000-0002-6329-382X
Rosser, Susan J.
Brennan, Paul M. https://orcid.org/0000-0002-7347-830X
Sieger, Dirk
Soufi, Abdenour https://orcid.org/0000-0002-3666-3266
Quezada, Sergio A. https://orcid.org/0000-0002-9763-1700
Pollard, Steven M. https://orcid.org/0000-0001-6428-0492
- License Information
-
More Information
Article History
Received: 7 December 2023
Accepted: 26 February 2026
First Online: 8 April 2026
Competing interests
: S.M.P., U.K. and M.M. are inventors of patents filed by the University of Edinburgh related to the discoveries in this study and to SSEs and associated sequences (WO2022162361A1). S.M.P. is founder of Trogenix, which is developing novel gene therapies for oncology, and is a paid consultant (part-time chief scientific officer, since February 2024) and shareholder. B.S., R. White, C.J.d.S. and M.P.C. have recently joined Trogenix as employees (since October 2025). S.A.Q. is a paid member of the scientific advisory board of Trogenix. P.M.B. and F.R. are paid external consultants for Trogenix related to ongoing clinical translation of these technologies. All other authors (N.A., K.F., Z.W., A.H., P.D., G.M., M.N., R. Willis., J.W., H.I.H., S.S., J.C.-W., S.G., G.M.M., F.G.C., A.W., S.J.R., D.S. and A.S.) declare no competing interests.
